Ad5-yCD/mutTK(SR39)rep-ADP
AXP000047.1 · Oncolytic virus
- Platform
- adenovirus (Ad5, replication-competent, ADP-overexpressing)
- Originator
- Henry Ford Health
- Sponsor
- Henry Ford Health
Names
| Name | Type | Source |
|---|---|---|
| Ad5-yCD/mutTK(SR39)rep-ADP | preferred name, code | curator, ncit |
Virus
- Role
- Oncolytic
- Family
- Adenoviridae
- Virus
- human adenovirus 5 (NCBI Taxonomy 28285)
- Strain
- Ad5 (yCD/mutTK(SR39)rep-ADP)
- Replication
- replicating
- Modifications
- replication-competent Ad5 with restored adenovirus death protein; E1B-55kDa retained
- Transgenes
- yCD/mutTK(SR39) suicide-gene fusion, adenovirus death protein (ADP)
- Route
- intratumoral
- Source
- evidence
Cross-references
- NCI Thesaurus
- C88330
Approvals
No regulatory approval recorded.
Clinical trials (2)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT05686798 | Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma. | Recruiting | Phase 1 | 2022-11-29 | 2027-01 | 18 | Astrocytoma; Brain Cancer; Brain Tumor; GBM; Glioblastoma; Glioblastoma Multiforme; Glioma; Malignant Astrocytoma; Malignant Glioma of Brain |
| NCT03029871 | Oncolytic Adenovirus-Mediated Gene Therapy for Lung Cancer | Withdrawn | Phase 1 | 2017-01-13 | 2018-12-31 | 0 | Non-small Cell Lung Cancer Stage I |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 32084409 | Tolerability and safety of EUS-injected adenovirus-mediated double-suicide gene therapy with chemotherapy in locally advanced pancreatic cancer: a phase 1 trial. | Gastrointestinal endoscopy | 2020 | name in abstract: Ad5-yCD/mutTK(SR39)rep-ADP |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 17551507 | Replication-competent adenovirus-mediated suicide gene therapy with radiation in a preclinical model of pancreatic cancer. | Molecular therapy : the journal of the American Society of Gene Therapy | 2007 | name in abstract: Ad5-yCD/mutTK(SR39)rep-ADP |
| PMID 16290236 | Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity. | Molecular therapy : the journal of the American Society of Gene Therapy | 2006 | name in abstract: Ad5-yCD/mutTK(SR39)rep-ADP |
Notes
Second-generation Henry Ford construct: yeast cytosine deaminase/mutant HSV-1 thymidine kinase (SR39) fusion suicide gene plus restored adenovirus death protein, used with 5-FC and valganciclovir and with radiotherapy. Trials in prostate cancer, pancreatic cancer and brain metastases (NCT03029871, NCT05686798).
How to cite
Ad5-yCD/mutTK(SR39)rep-ADP (AXP000047.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000047.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.